GO
Loading...

Enter multiple symbols separated by commas

Vertex Pharmaceuticals Inc

More

  • Top 10 highest-paid CEOs Tuesday, 26 May 2015 | 6:00 AM ET

    1. David Zaslav, Discovery Communications, $156.1 million, up 368 percent. 2. Leslie Moonves, CBS, $54.4 million, down 17 percent. 3. Philippe Dauman, Viacom, $44.3 million, up 19 percent.

  • CEO pay: biggest raises and biggest cuts of 2014 Tuesday, 26 May 2015 | 6:00 AM ET

    1. Richard Hayne, Urban Outfitters, $535,636, up 682 percent. 2. David Zaslav, Discovery Communications, $156.1 million, up 368 percent. 3. John Richels, Devon Energy, $14.9 million, up 301 percent.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • *FDA slated to make decision on treatment on July 5. FDA questioned whether Vertex Pharmaceuticals Inc's experimental combination therapy for cystic fibrosis had an added benefit over the company's already approved therapy, Kalydeco, in patients with the most common genetic mutation behind the deadly disease. The FDA is slated to make a decision on Orkambi...

  • May 8- Vertex Pharmaceuticals Inc's combination of an experimental compound and an approved drug significantyly improved lung function in cystic fibrosis patients with the most common genetic mutation underlying the disease, FDA staff said. The FDA is trying to ask the panel if the evidence is enough to show that the combination's benefit is significantly...

  • May 8- FDA staff reviewers questioned whether Vertex Pharmaceuticals Inc's experimental cystic fibrosis drug added any benefit over its already approved therapy, Kalydeco, in patients with the most common genetic mutation underlying the disease. Vertex is seeking approval for the combination of the compound lumacafotor and Kalydeco to treat CF patients...

  • May 4- Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop...

  • Goldman's top picks Tuesday, 7 Apr 2015 | 2:11 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Brian Sullivan and Dom Chu will list the top 40 cheapest stock picks from Goldman Sachs.

  • 10 companies hurtling into world of hurt Tuesday, 7 Apr 2015 | 12:11 PM ET
    An Amazon.com worker picks orders at an Amazon fulfillment center in Tracy, California.

    Earnings season is almost here for most companies. But others are hurtling straight into loss season. USA Today reports.

  • Obama seeks $215 million for 'precision medicine' Friday, 30 Jan 2015 | 6:00 AM ET
    President Barack Obama delivers the State of the Union address on January 20, 2015 in the House Chamber of the U.S. Capitol in Washington.

    President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.

  • Drugmakers get mysterious invites to White House Wednesday, 28 Jan 2015 | 5:06 PM ET
    President Barack Obama

    The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • Midday movers: Target, JetBlue, Qualcomm & more Wednesday, 19 Nov 2014 | 1:09 PM ET
    NYSE New York Stock Exchange traders markets

    Some of Wednesday's midday movers:

  • Bonds hold losses after weak 2-year note auction Tuesday, 28 Oct 2014 | 2:39 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. Treasury yields continued to rise on Tuesday amid data and expectations of Fed action.

  • What's boosting healthiest sector in S&P this year Monday, 27 Oct 2014 | 1:43 PM ET

    Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.

  • Midday movers: GoPro, Tesla Motors, Yahoo & more Monday, 13 Oct 2014 | 1:03 PM ET
    New York Stock Exchange NYSE

    Some of Monday's midday movers:

  • Traders work on the floor of the New York Stock Exchange in New York.

    Stocks cut losses to close mixed on Thursday as geopolitical tensions lingered ahead of consumer data.

  • Traders work on the floor of the New York Stock Exchange, Aug. 1, 2014, in New York.

    U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • This liver disease could rival hepatitis C Tuesday, 15 Jul 2014 | 8:06 AM ET

    The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.